A new dawn of hope illuminates the Democratic Republic of Congo as a critical Ebola treatment trial rapidly takes shape. In an unprecedented move, scientists have initiated a groundbreaking research program within weeks of the latest outbreak’s declaration, aiming to drastically cut mortality rates from the deadly Bundibugyo strain of the virus.
The pace is simply astonishing. Historically, establishing such extensive clinical research can consume over a year. Yet, just six short weeks after the World Health Organization (WHO) formally declared the outbreak a public health emergency of international concern on May 17, patients began enrolling. This swift action reflects the desperate need for approved interventions in a region ravaged by a disease for which no specific cure currently exists.
Life in Bunia, the beleaguered capital of Ituri province, is fraught with anxiety. The virus rages, relentlessly pushing communities to their financial limits. “I hope these drug trials proceed quickly,” pleaded Neema Haba, a mother of three and local banana seller, expressing the pervasive sentiment of impatience and despair among residents. “Financially, we are being driven to the brink by this outbreak and nothing is going right. We are struggling to provide for our children.” The latest figures paint a grim picture: 1,792 confirmed cases and 625 deaths attributed to the Bundibugyo strain as of July 9, according to local reports. The WHO ominously suggests the outbreak remains “in the expansion phase.”
Advancing the Ebola Treatment Trial
The immediate response, reliant on tracing contacts, isolating the sick, and careful burial protocols, faces immense hurdles. Community distrust and a highly mobile populace mean only about 75% of known contacts are reliably traced. Disturbingly, frontline workers recently halted operations, protesting a severe lack of pay. Ovide Maliabo, a driver for a burial team in Rwampara, described the peril, recounting a near-lynching incident. “It’s a shame that we aren’t being financially supported,” he lamented. His colleague, Bahati John, the team head, even lost a tooth in an attack. They claim not to have received a “single penny” since mid-May, leaving their families in distress. While DRC officials assert payments were made, full resumption of services remains uncertain, further exacerbated by the closure of Bunia’s local airport, hindering logistical support and even the supply of banknotes.
Against this backdrop of challenges, all eyes turn to the scientific community. The Partners treatment trial has bravely begun, featuring two promising investigational drugs: remdesivir and MBP134. Patients will be randomly assigned to receive either drug, a combination, or standard supportive care. Remdesivir, an antiviral from Gilead Sciences, and MBP134, a monoclonal antibody from Mapp Biopharmaceutical, both demonstrated significant efficacy against the Bundibugyo virus in animal models. Now, the true test begins in human patients.
“They showed great efficacy, but now we need to test it in humans. Basically, what we want to see is if they indeed can lower mortality,” explained Prof. Laurens Liesenborghs of the Institute of Tropical Medicine, Antwerp, involved in the trial. While the Bundibugyo strain typically exhibits a lower fatality rate than the Zaire strain—killing about one in three of those infected—any proven effective intervention would be a monumental victory. Researchers are diligently monitoring for a statistically significant drop in death rates among those receiving the experimental treatments within this crucial Ebola treatment trial.
Previous trials targeting Zaire strain Ebola, utilizing monoclonal antibodies, saw death rates plunge from 50% to 35%. Scientists harbor hopes for a similar magnitude of improvement here. The trial structure is ingeniously flexible, allowing for the inclusion of additional treatments as they emerge. Prof. Liesenborghs estimates 700 to 1,000 patients will be needed to yield conclusive results. While one site is operational, a swift expansion to additional locations is crucial, though the overall timeline remains dependent on the outbreak’s trajectory.
Crucially, global health authority experts confirm that sufficient remdesivir and MBP134 have been generously donated by Gilead and the U.S. government, respectively, to treat 1,200 patients. Discussions are underway to guarantee a sustainable supply post-trial, should these treatments prove both safe and effective. A truly inclusive approach is being adopted; patients of all ages, including pregnant and breastfeeding women—often unfairly excluded from medical research—are eligible to participate. “Here the benefit is potentially very high because you offer a potentially life-saving treatment to someone who has a very high chance of dying,” noted Prof. Liesenborghs, weighing the risk-benefit carefully, especially given Ebola’s tragic link to miscarriages and the drugs’ safety in animal pregnancy studies.
Prof. Amanda Rojek of the University of Oxford, international principal investigator for Partners, lauded the rapid initiation. “It’s just fantastic we’ve managed to get started so quickly.” She credits the robust scientific leadership within the DRC, which possesses a commendable history of hosting major trials for Ebola and other diseases like mpox. Reflecting on the 2014-16 West African Ebola crisis, where clinical trials took over a year to commence, she expressed immense pride in the DRC’s National Biomedical Research Institute (INRB) team for their six-week achievement. Simplification, a lesson learned from the Covid-19 Recovery trial, remains central to the design of this pivotal Ebola treatment trial.
Sponsored by the WHO and supported by the Wellcome Trust, FCDO, and UKRI, this monumental effort is lauded by leaders like Prof. Yap Boum of Africa CDC. He acknowledges the continued danger but emphasizes, “These trials will enable us to access treatment, and when we treat people, it also sends a message to the community.” Furthermore, another trial is set to commence this week, investigating whether obeldesivir can prevent disease in Bundibugyo contacts. Securing the necessary $18 million for this additional research remains a pressing goal, with $6 million already committed.
About the Author
